{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:49:27Z","timestamp":1777481367265,"version":"3.51.4"},"reference-count":57,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>On a worldwide scale, the outbreak of the Severe Acute Respiratory Syndrome Coronavirus\n2 (SARS-CoV-2) has led to extensive damage to the health system as well as the global economy.\nHitherto, there has been no approved drug or vaccine for this disease. Therefore, the use of general antiviral\ndrugs is at the first line of treatment, though complicated with limited effectiveness and systemic\nside effects. Given the pathophysiology of the disease, researchers have proposed various strategies not\nonly to find a more specific therapeutic way but also to reduce the side effects. One strategy to accomplish\nthese goals is to use CRISPR\/Cas13 system. Recently, a group of scientists has used the\nCRISPR\/Cas13 system, which is highly effective in eliminating the genome of RNA viruses. Due to\nthe RNA nature of the coronavirus genome, it seems that this system can be effective against the disease.\nThe main challenge regarding the application of this system is to deliver it to the target cells efficiently.\nTo solve this challenge, it seems that using virosomes with protein S on their membrane surface\ncan be helpful. Studies have shown that protein S interacts with its specific receptor in target cells\nnamed Angiotensin-Converting Enzyme 2 (ACE2). Here, we propose if CRISPR\/Cas13 gene constructs\nreach the infected cells efficiently using a virosomal delivery system, the virus genome will be\ncleaved and inactivated. Considering the pathophysiology of the disease, an important step to implement\nthis hypothesis is to embed protein S on the membrane surface of virosomes to facilitate the delivery\nof gene constructs to the target cells.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201021666201009154517","type":"journal-article","created":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T07:47:25Z","timestamp":1602402445000},"page":"1149-1155","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted Delivery of CRISPR\/Cas13 as a Promising Therapeutic Approach to Treat SARS-CoV-2"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-8759","authenticated-orcid":true,"given":"Kazem","family":"Abbaszadeh-Goudarzi","sequence":"first","affiliation":[{"name":"Cellular and Molecular Research Center, Sabzevar University of Medical Science, Sabzevar,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-4077","authenticated-orcid":true,"given":"Mohammad H.","family":"Nematollahi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4442-9605","authenticated-orcid":true,"given":"Hashem","family":"Khanbabaei","sequence":"additional","affiliation":[{"name":"Medical Physics Department, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-818X","authenticated-orcid":true,"given":"Hossein H.","family":"Nave","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Virology, School of Medicine, Kerman University of Medical Sciences, Kerman,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-2565","authenticated-orcid":true,"given":"Hamid R.","family":"Mirzaei","sequence":"additional","affiliation":[{"name":"Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-8572","authenticated-orcid":true,"given":"Hossein","family":"Pourghadamyari","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":true,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad,Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e13209","DOI":"10.1111\/eci.13209","volume":"2020","author":"Bassetti M.","year":"2019","unstructured":"Bassetti M.; Vena A.; Giacobbe D.R.; The novel Chinese coronavirus. \u2010nCoV) infections: Challenges for fighting the storm. Eur J Clin Invest 2019,2020(3),e13209","journal-title":"Eur J Clin Invest"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40169-020-00271-z","volume":"9","author":"She J.","year":"2020","unstructured":"She J.; Jiang J.; Ye L.; Hu L.; Bai C.; Song Y.; 2019 novel coronavirus of pneumonia in Wuhan, China: Emerging attack and management strategies. Clin Transl Med 2020,9(1),19","journal-title":"Clin Transl Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1473-3099(20)30227-9","volume":"20","author":"Tuite A.R.","year":"2020","unstructured":"Tuite A.R.; Ng V.; Rees E.; Fisman D.; Estimation of COVID-19 outbreak size in Italy. Lancet Infect Dis 2020,20(5),537","journal-title":"Lancet Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/jmv.25722","volume":"92","author":"Sun P.","year":"2020","unstructured":"Sun P.; Lu X.; Xu C.; Sun W.; Pan B.; Understanding of COVID-19 based on current evidence. J Med Virol 2020,92(6),548-551","journal-title":"J Med Virol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.2214\/AJR.20.22954","volume":"214","author":"Li Y.","year":"2020","unstructured":"Li Y.; Xia L.; Coronavirus Disease 2019 (COVID-19): Role of chest CT in diagnosis and management. AJR Am J Roentgenol 2020,214(6),1280-1286","journal-title":"AJR Am J Roentgenol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2020.03.004","volume":"94","author":"Wu D.","year":"2020","unstructured":"Wu D.; Wu T.; Liu Q.; Yang Z.; The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020,94,44-48","journal-title":"Int J Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"Stebbing J.","year":"2020","unstructured":"Stebbing J.; Phelan A.; Griffin I.; Tucker C.; Oechsle O.; Smith D.; Richardson P.; COVID-19: Combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020,20(4),400-402","journal-title":"Lancet Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.2020.4812","volume":"323","author":"Patel A.B.","year":"2020","unstructured":"Patel A.B.; Verma A.; COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA 2020,323(18),1769-1770","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr\u00fcger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N-H.; Nitsche A.; M\u00fcller M.A.; Drosten C.; P\u00f6hlmann S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8","journal-title":"Cell"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"Gurwitz D.","year":"2020","unstructured":"Gurwitz D.; Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020,81(5),537-540","journal-title":"Drug Dev Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"Dong L.","year":"2020","unstructured":"Dong L.; Hu S.; Gao J.; Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020,14(1),58-60","journal-title":"Drug Discov Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","volume":"73","author":"Fung T.S.","year":"2019","unstructured":"Fung T.S.; Liu D.X.; Human coronavirus: Host-pathogen interaction. Annu Rev Microbiol 2019,73,529-557","journal-title":"Annu Rev Microbiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","volume":"66","author":"Masters P.S.","year":"2006","unstructured":"Masters P.S.; The molecular biology of coronaviruses. Adv Virus Res 2006,66,193-292","journal-title":"Adv Virus Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"Li F.","year":"2016","unstructured":"Li F.; Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016,3(1),237-261","journal-title":"Annu Rev Virol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Penninger J.M.; Li Y.; Zhong N.; Slutsky A.S.; Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med 2020,46(4),586-590","journal-title":"Intensive Care Med"},{"key":"ref=16","author":"Sun K.","year":"2020","unstructured":"Sun K.; Gu L.; Ma L.; Duan Y.; Atlas of ACE2 gene expression\nin mammals reveals novel insights in transmission of SARS-Cov-2;\nBioRxiv, 2020 https:\/\/www.biorxiv.org\/content\/10.1101\/2020.03.30.015644v1"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","volume":"6","author":"Cao Y.","year":"2020","unstructured":"Cao Y.; Li L.; Feng Z.; Wan S.; Huang P.; Sun X.; Wen F.; Huang X.; Ning G.; Wang W.; Comparative genetic analysis of the novel coronavirus (2019-nCoV\/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 2020,6(1),11","journal-title":"Cell Discov"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/JVI.02202-13","volume":"88","author":"Heurich A.","year":"2014","unstructured":"Heurich A.; Hofmann-Winkler H.; Gierer S.; Liepold T.; Jahn O.; P\u00f6hlmann S.; TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2014,88(2),1293-1307","journal-title":"J Virol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1128\/JVI.02615-14","volume":"89","author":"Li F.","year":"2015","unstructured":"Li F.; Receptor recognition mechanisms of coronaviruses: A decade of structural studies. J Virol 2015,89(4),1954-1964","journal-title":"J Virol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","volume":"12","author":"Hofmann H.","year":"2004","unstructured":"Hofmann H.; P\u00f6hlmann S.; Cellular entry of the SARS coronavirus. Trends Microbiol 2004,12(10),466-472","journal-title":"Trends Microbiol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/ptr.6663","volume":"34","author":"Liczbi\u0144ski P.","year":"2020","unstructured":"Liczbi\u0144ski P.; Micha\u0142owicz J.; Bukowska B.J.P.R.; Molecular mechanism of curcumin action in signaling pathways: Review of the latest research. Phytother Res 2020,34(8),1992-2005","journal-title":"Phytother Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","volume":"109","author":"Rothan H.A.","year":"2020","unstructured":"Rothan H.A.; Byrareddy S.N.; The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020,109,102433","journal-title":"J Autoimmun"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"Jinek M.","year":"2012","unstructured":"Jinek M.; Chylinski K.; Fonfara I.; Hauer M.; Doudna J.A.; Charpentier E.; A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012,337(6096),816-821","journal-title":"Science"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1038\/mtna.2016.58","volume":"5","author":"Dai W-J.","year":"2016","unstructured":"Dai W-J.; Zhu L-Y.; Yan Z-Y.; Xu Y.; Wang Q-L.; Lu X-J.; CRISPR-Cas9 for in vivo gene therapy: Promise and hurdles. Mol Ther Nucleic Acids 2016,5,e349","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=25","first-page":"197","volume":"1866","author":"Yi L.","year":"2016","unstructured":"Yi L.; Li J.; CRISPR-Cas9 therapeutics in cancer: Promising strategies and present challenges. Biochim Biophys Acta 2016,1866(2),197-207","journal-title":"Biochim Biophys Acta"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"Lino C.A.","year":"2018","unstructured":"Lino C.A.; Harper J.C.; Carney J.P.; Timlin J.A.; Delivering CRISPR: A review of the challenges and approaches. Drug Deliv 2018,25(1),1234-1257","journal-title":"Drug Deliv"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trsl.2015.09.008","volume":"168","author":"Savi\u0107 N.","year":"2016","unstructured":"Savi\u0107 N.; Schwank G.; Advances in therapeutic CRISPR\/Cas9 genome editing. Transl Res 2016,168,15-21","journal-title":"Transl Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"Zhang X-H.","year":"2015","unstructured":"Zhang X-H.; Tee L.Y.; Wang X-G.; Huang Q-S.; Yang S-H.; Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Ther Nucleic Acids 2015,4,e264","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"Doench J.G.","year":"2016","unstructured":"Doench J.G.; Fusi N.; Sullender M.; Hegde M.; Vaimberg E.W.; Donovan K.F.; Smith I.; Tothova Z.; Wilen C.; Orchard R.; Virgin H.W.; Listgarten J.; Root D.E.; Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 2016,34(2),184-191","journal-title":"Nat Biotechnol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nchembio.2559","volume":"14","author":"Yin H.","year":"2018","unstructured":"Yin H.; Song C-Q.; Suresh S.; Kwan S-Y.; Wu Q.; Walsh S.; Ding J.; Bogorad R.L.; Zhu L.J.; Wolfe S.A.; Koteliansky V.; Xue W.; Langer R.; Anderson D.G.; Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nat Chem Biol 2018,14(3),311-316","journal-title":"Nat Chem Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","volume":"32","author":"Fu Y.","year":"2014","unstructured":"Fu Y.; Sander J.D.; Reyon D.; Cascio V.M.; Joung J.K.; Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 2014,32(3),279-284","journal-title":"Nat Biotechnol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"Abudayyeh O.O.","year":"2017","unstructured":"Abudayyeh O.O.; Gootenberg J.S.; Essletzbichler P.; Han S.; Joung J.; Belanto J.J.; Verdine V.; Cox D.B.T.; Kellner M.J.; Regev A.; Lander E.S.; Voytas D.F.; Ting A.Y.; Zhang F.; RNA targeting with CRISPR-Cas13. Nature 2017,550(7675),280-284","journal-title":"Nature"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","volume":"173","author":"Konermann S.","year":"2018","unstructured":"Konermann S.; Lotfy P.; Brideau N.J.; Oki J.; Shokhirev M.N.; Hsu P.D.; Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 2018,173(3),665-676","journal-title":"Cell"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fgene.2018.00134","volume":"9","author":"Matsoukas I.G.","year":"2018","unstructured":"Matsoukas I.G.; Commentary: RNA editing with CRISPR-Cas13. Front Genet 2018,9,134","journal-title":"Front Genet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"Cox D.B.T.","year":"2017","unstructured":"Cox D.B.T.; Gootenberg J.S.; Abudayyeh O.O.; Franklin B.; Kellner M.J.; Joung J.; Zhang F.; RNA editing with CRISPR-Cas13. Science 2017,358(6366),1019-1027","journal-title":"Science"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10565-019-09489-1","volume":"35","author":"Yan F.","year":"2019","unstructured":"Yan F.; Wang W.; Zhang J.; CRISPR-Cas12 and Cas13: The lesser known siblings of CRISPR-Cas9. Cell Biol Toxicol 2019,35,489-492","journal-title":"Cell Biol Toxicol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.molcel.2019.09.013","volume":"76","author":"Freije C.A.","year":"2019","unstructured":"Freije C.A.; Myhrvold C.; Boehm C.K.; Lin A.E.; Welch N.L.; Carter A.; Metsky H.C.; Luo C.Y.; Abudayyeh O.O.; Gootenberg J.S.; Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell 2019,76(5),826-837","journal-title":"Mol Cell"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13059-019-1881-2","volume":"20","author":"Mahas A.","year":"2019","unstructured":"Mahas A.; Aman R.; Mahfouz M.; CRISPR-Cas13d mediates robust RNA virus interference in plants. Genome Biol 2019,20(1),263","journal-title":"Genome Biol"},{"key":"ref=39","author":"Corman V.","year":"2020","unstructured":"Corman V.; Bleicker T.; Br\u00fcnink S.; Drosten C.; Zambon M.;  Diagnostic detection of 2019-nCoV by real-time RT-PCR 2020","journal-title":"Diagnostic detection of 2019-nCoV by real-time RT-PCR"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7883\/yoken.JJID.2020.061","volume":"73","author":"Shirato K.","year":"2020","unstructured":"Shirato K.; Nao N.; Katano H.; Takayama I.; Saito S.; Kato F.; Katoh H.; Sakata M.; Nakatsu Y.; Mori Y.; Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis 2020,73(4),304-307","journal-title":"Jpn J Infect Dis"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2013.11.041","volume":"459","author":"Ibraheem D.","year":"2014","unstructured":"Ibraheem D.; Elaissari A.; Fessi H.; Gene therapy and DNA delivery systems. Int J Pharm 2014,459(1-2),70-83","journal-title":"Int J Pharm"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"10398","DOI":"10.1021\/acsami.8b01712","volume":"10","author":"Ruan C.","year":"2018","unstructured":"Ruan C.; Liu L.; Wang Q.; Chen X.; Chen Q.; Lu Y.; Zhang Y.; He X.; Zhang Y.; Guo Q.; Sun T.; Jiang C.; Reactive oxygen species-biodegradable gene carrier for the targeting therapy of breast cancer. ACS Appl Mater Interfaces 2018,10(12),10398-10408","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.1002\/cpmo.58","author":"Chen Y.H.","year":"2018","unstructured":"Chen Y.H.; Keiser M.S.; Davidson B.L.; Viral vectors for gene transfer. Curr Protoc Mouse Biol 2018","journal-title":"Curr Protoc Mouse Biol"},{"key":"ref=44","first-page":"1781","volume":"46","author":"Nematollahi M.H.","year":"2018","unstructured":"Nematollahi M.H.; Torkzadeh-Mahanai M.; Pardakhty A.; Ebrahimi Meimand H.A.; Asadikaram G.; Ternary complex of plasmid DNA with NLS-Mu-Mu protein and cationic niosome for biocompatible and efficient gene delivery: A comparative study with protamine and lipofectamine. Artif Cells Nanomed Biotechnol 2018,46(8),1781-1791","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.msec.2018.09.026","volume":"94","author":"Barani M.","year":"2019","unstructured":"Barani M.; Nematollahi M.H.; Zaboli M.; Mirzaei M.; Torkzadeh-Mahani M.; Pardakhty A.; Karam G.A.; In silico and in vitro study of magnetic niosomes for gene delivery: The effect of ergosterol and cholesterol. Mater Sci Eng C 2019,94,234-246","journal-title":"Mater Sci Eng C"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40005-016-0260-1","volume":"46","author":"Kim J-S.","year":"2016","unstructured":"Kim J-S.; Liposomal drug delivery system. J Pharm Investig 2016,46(4),387-392","journal-title":"J Pharm Investig"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.addr.2011.03.007","volume":"64","author":"Kaneda Y.","year":"2012","unstructured":"Kaneda Y.; Virosome: A novel vector to enable multi-modal strategies for cancer therapy. Adv Drug Deliv Rev 2012,64(8),730-738","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5958\/0975-4377.2019.00050.8","volume":"11","author":"Rathor S.","year":"2019","unstructured":"Rathor S.; Soni P.; Lal D.; Unique drug delivery system. Virosomes Res J Pharm Dos Forms Technol 2019,11(4),304-308","journal-title":"Virosomes Res J Pharm Dos Forms Technol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(75)92130-3","volume":"2","author":"Almeida J.D.","year":"1975","unstructured":"Almeida J.D.; Edwards D.C.; Brand C.M.; Heath T.D.; Formation of virosomes from influenza subunits and liposomes. Lancet 1975,2(7941),899-901","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.addr.2004.09.005","volume":"57","author":"Daemen T.","year":"2005","unstructured":"Daemen T.; de Mare A.; Bungener L.; de Jonge J.; Huckriede A.; Wilschut J.; Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005,57(3),451-463","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/intimm\/dxh249","volume":"17","author":"Amacker M.","year":"2005","unstructured":"Amacker M.; Engler O.; Kammer A.R.; Vadrucci S.; Oberholzer D.; Cerny A.; Zurbriggen R.; Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 2005,17(6),695-704","journal-title":"Int Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/08982104.2016.1144205","volume":"27","author":"Mohammadzadeh Y.","year":"2017","unstructured":"Mohammadzadeh Y.; Gholami S.; Rasouli N.; Sarrafzadeh S.; Seyed Tabib N.S.; Samiee Aref M.H.; Abdoli A.; Biglari P.; Fotouhi F.; Farahmand B.; Tavassoti Kheiri M.; Jamali A.; Introduction of cationic virosome derived from vesicular stomatitis virus as a novel gene delivery system for sf9 cells. J Liposome Res 2017,27(2),83-89","journal-title":"J Liposome Res"},{"key":"ref=53","author":"Dong W.","year":"2016","unstructured":"Dong W.; Rijken P.; Ugwoke M.;  Method for preparing virosomes U.S. Patent 0,199,480A12016","journal-title":"Method for preparing virosomes"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.22270\/jddt.v8i6-s.2163","volume":"8","author":"Shaikh S.N.","year":"2018","unstructured":"Shaikh S.N.; Raza S.; Ansari M.A.; Khan G.; Athar S.H.M.; Overview on virosomes as a novel carrier for drug delivery. J Drug Deliv Ther 2018,8(6-s),429-434","journal-title":"J Drug Deliv Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e0194179","DOI":"10.1371\/journal.pone.0194179","volume":"13","author":"Bartelds R.","year":"2018","unstructured":"Bartelds R.; Nematollahi M.H.; Pols T.; Stuart M.C.; Pardakhty A.; Asadikaram G.; Poolman B.; Niosomes, an alternative for liposomal delivery. PLoS One 2018,13(4),e0194179","journal-title":"PLoS One"},{"key":"ref=56","first-page":"459","volume":"35","author":"Kim H.S.","year":"2002","unstructured":"Kim H.S.; Park Y.S.; Effect of lipid compositions on gene transfer into 293 cells using Sendai F\/HN-virosomes. J Biochem Mol Biol 2002,35(5),459-464","journal-title":"J Biochem Mol Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1042\/BJ20061756","volume":"405","author":"de Jonge J.","year":"2007","unstructured":"de Jonge J.; Leenhouts J.M.; Holtrop M.; Schoen P.; Scherrer P.; Cullis P.R.; Wilschut J.; Huckriede A.; Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem J 2007,405(1),41-49","journal-title":"Biochem J"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201021666201009154517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186771\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201021666201009154517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T15:02:51Z","timestamp":1656169371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186771\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201021666201009154517","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}